104 related articles for article (PubMed ID: 25014506)
1. Genetic variance in ABCB1 and CYP3A5 does not contribute toward the development of chronic kidney disease after liver transplantation.
Tapirdamaz Ö; Hesselink DA; el Bouazzaoui S; Azimpour M; Hansen B; van der Laan LJ; Polak WG; Kwekkeboom J; van Schaik RH; van Gelder T; Metselaar HJ
Pharmacogenet Genomics; 2014 Sep; 24(9):427-35. PubMed ID: 25014506
[TBL] [Abstract][Full Text] [Related]
2. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.
Staatz CE; Goodman LK; Tett SE
Clin Pharmacokinet; 2010 Apr; 49(4):207-21. PubMed ID: 20214406
[TBL] [Abstract][Full Text] [Related]
3. CYP3A5 and ABCB1 polymorphisms in donor and recipient: impact on Tacrolimus dose requirements and clinical outcome after renal transplantation.
Glowacki F; Lionet A; Buob D; Labalette M; Allorge D; Provôt F; Hazzan M; Noël C; Broly F; Cauffiez C
Nephrol Dial Transplant; 2011 Sep; 26(9):3046-50. PubMed ID: 21677300
[TBL] [Abstract][Full Text] [Related]
4. Influence of CYP3A5 genotypes on tacrolimus dose requirement: age and its pharmacological interaction with ABCB1 genetics in the Chinese paediatric liver transplantation.
Yang TH; Chen YK; Xue F; Han LZ; Shen CH; Zhou T; Luo Y; Zhang JJ; Xia Q
Int J Clin Pract Suppl; 2015 May; (183):53-62. PubMed ID: 26176181
[TBL] [Abstract][Full Text] [Related]
5. Relationship of CYP3A5 genotype and ABCB1 diplotype to tacrolimus disposition in Brazilian kidney transplant patients.
Cusinato DA; Lacchini R; Romao EA; Moysés-Neto M; Coelho EB
Br J Clin Pharmacol; 2014 Aug; 78(2):364-72. PubMed ID: 24528196
[TBL] [Abstract][Full Text] [Related]
6. Effect of CYP3A5 and ABCB1 Gene Polymorphisms on Tacrolimus Blood Concentration in Renal Transplant Recipients.
Yildirim E; Şahin G; Kaltuş Z; Çolak E
Clin Lab; 2019 Nov; 65(11):. PubMed ID: 31710427
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetics of calcineurin inhibitors in Brazilian renal transplant patients.
Santoro A; Felipe CR; Tedesco-Silva H; Medina-Pestana JO; Struchiner CJ; Ojopi EB; Suarez-Kurtz G
Pharmacogenomics; 2011 Sep; 12(9):1293-303. PubMed ID: 21806386
[TBL] [Abstract][Full Text] [Related]
8. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients.
Quteineh L; Verstuyft C; Furlan V; Durrbach A; Letierce A; Ferlicot S; Taburet AM; Charpentier B; Becquemont L
Basic Clin Pharmacol Toxicol; 2008 Dec; 103(6):546-52. PubMed ID: 19067682
[TBL] [Abstract][Full Text] [Related]
9. 1199G>A and 2677G>T/A polymorphisms of ABCB1 independently affect tacrolimus concentration in hepatic tissue after liver transplantation.
Elens L; Capron A; Kerckhove VV; Lerut J; Mourad M; Lison D; Wallemacq P; Haufroid V
Pharmacogenet Genomics; 2007 Oct; 17(10):873-83. PubMed ID: 17885626
[TBL] [Abstract][Full Text] [Related]
10. CYP3A5 and ABCB1 polymorphisms in living donors do not impact clinical outcome after kidney transplantation.
Yang L; de Winter BC; van Schaik RH; Xie RX; Li Y; Andrews LM; Shuker N; Bahmany S; Koch B; van Gelder T; Hesselink DA
Pharmacogenomics; 2018 Jul; 19(11):895-903. PubMed ID: 29991328
[TBL] [Abstract][Full Text] [Related]
11. Impact of donor and recipient CYP3A5 and ABCB1 genetic polymorphisms on tacrolimus dosage requirements and rejection in Caucasian Spanish liver transplant patients.
Gómez-Bravo MA; Salcedo M; Fondevila C; Suarez F; Castellote J; Rufian S; Pons JA; Alamo JM; Millán O; Brunet M
J Clin Pharmacol; 2013 Nov; 53(11):1146-54. PubMed ID: 23900887
[TBL] [Abstract][Full Text] [Related]
12. CYP3A5 and ABCB1 polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation.
Capron A; Mourad M; De Meyer M; De Pauw L; Eddour DC; Latinne D; Elens L; Haufroid V; Wallemacq P
Pharmacogenomics; 2010 May; 11(5):703-14. PubMed ID: 20415563
[TBL] [Abstract][Full Text] [Related]
13. CYP3A5 and CYP3A4, but not ABCB1 polymorphisms affect tacrolimus dose-adjusted trough concentrations in kidney transplant recipients.
Kurzawski M; Dąbrowska J; Dziewanowski K; Domański L; Perużyńska M; Droździk M
Pharmacogenomics; 2014 Feb; 15(2):179-88. PubMed ID: 24444408
[TBL] [Abstract][Full Text] [Related]
14. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients.
Fukudo M; Yano I; Yoshimura A; Masuda S; Uesugi M; Hosohata K; Katsura T; Ogura Y; Oike F; Takada Y; Uemoto S; Inui K
Pharmacogenet Genomics; 2008 May; 18(5):413-23. PubMed ID: 18408564
[TBL] [Abstract][Full Text] [Related]
15. Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients.
Wei-lin W; Jing J; Shu-sen Z; Li-hua W; Ting-bo L; Song-feng Y; Sheng Y
Liver Transpl; 2006 May; 12(5):775-80. PubMed ID: 16628701
[TBL] [Abstract][Full Text] [Related]
16. The functional implications of common genetic variation in CYP3A5 and ABCB1 in human proximal tubule cells.
Knops N; van den Heuvel LP; Masereeuw R; Bongaers I; de Loor H; Levtchenko E; Kuypers D
Mol Pharm; 2015 Mar; 12(3):758-68. PubMed ID: 25590378
[TBL] [Abstract][Full Text] [Related]
17. Donor and recipient P450 gene polymorphisms influence individual pharmacological effects of tacrolimus in Chinese liver transplantation patients.
Liu J; Ouyang Y; Chen D; Yao B; Lin D; Li Z; Zang Y; Liu H; Fu X
Int Immunopharmacol; 2018 Apr; 57():18-24. PubMed ID: 29454235
[TBL] [Abstract][Full Text] [Related]
18. Personalized tacrolimus dose requirement by CYP3A5 but not ABCB1 or ACE genotyping in both recipient and donor after pediatric liver transplantation.
Chen YK; Han LZ; Xue F; Shen CH; Lu J; Yang TH; Zhang JJ; Xia Q
PLoS One; 2014; 9(10):e109464. PubMed ID: 25310192
[TBL] [Abstract][Full Text] [Related]
19. Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation.
Niioka T; Satoh S; Kagaya H; Numakura K; Inoue T; Saito M; Narita S; Tsuchiya N; Habuchi T; Miura M
Transplantation; 2012 Nov; 94(10):1013-9. PubMed ID: 23073468
[TBL] [Abstract][Full Text] [Related]
20. Liver Transplant Patient Carriers of Polymorphism Cyp3a5*1 Donors May Need More Doses of Tacrolimus From the First Month After Transplantation.
Argudo A; González de Aledo JM; Alía P; Ramírez P; Serrano T; Fabregat J; Castellote J
Transplant Proc; 2015 Oct; 47(8):2388-92. PubMed ID: 26518936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]